1 month Mizuho Upgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to Strong-BuyMarketBeat
Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday.
Nasdaq 100 · Pharmaceuticals · Science
X